UNASSIGNED: This study investigates a dual-targeting strategy in acute myeloid leukemia (AML), focusing on FLT3 and CD99. The approach demonstrates enhanced therapeutic potential, presenting a novel option for AML treatment.
FLT3 / CD99 基于双特异性抗体的纳米颗粒 ( BiAbs ) 用于急性髓系白血病。
Mesh : fms-Like Tyrosine Kinase 3 / genetics metabolism Animals Leukemia, Myeloid, Acute / drug therapy immunology metabolism Humans Antibodies, Bispecific / pharmacology therapeutic use Mice Nanoparticles / chemistry 12E7 Antigen / metabolism genetics Cell Line, Tumor Xenograft Model Antitumor Assays Female
来 源:
DOI:10.1158/2767-9764.CRC-24-0096
PDF(Pubmed)